Expert Interview
Discussing the AstraZenaca's B7-H4–targeting topoisomerase 1 inhibitor antibody-drug conjugate, puxitatug samrotecan (AZD8205), and the results from the phase 1/2a BLUESTAR study in endometrial cancer presented at the 2025 SGO Meeting.
Ticker(s): AZNInstitution: Albert Einstein College of Medicine
- Professor of Clinical Obstetrics & Gynecology and Women's Health in the department of Gynecological Oncology.
- Cares for 100 patients with endometrial cancer per year
- Research interests include improving palliative medicine for women with gynecological cancers and leading over 20 industry sponsored, cooperative group, and investigator initiated behavioral and chemotherapeutic trials as institutional principle investigator.
Roughly how many patients do you treat with endometrial cancer per year?
Added By: sara_adminHow do you think puxitatug samrotecan will fit into the current treatment landscape?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of puxitatug samrotecan, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
